Roivant Sciences Ltd
(NAS:ROIV)
$
11.85
0.07 (0.59%)
Market Cap: 8.76 Bil
Enterprise Value: 3.42 Bil
PE Ratio: 2.12
PB Ratio: 1.60
GF Score: 41/100 Roivant Sciences Ltd (ROIV) Transcripts
- Q4 2024 Roivant Sciences Ltd Earnings Call TranscriptMay 30, 2024$10.39 (-3.17%)Earnings
- Q3 2024 Roivant Sciences Ltd Earnings Call TranscriptFeb 13, 2024$10.8 (-0.64%)Earnings
- Roivant Sciences Ltd at Guggenheim Healthcare Talks Biotechnology Conference TranscriptFeb 07, 2024
- Roivant Sciences Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Roivant Sciences Ltd at Piper Sandler Healthcare Conference TranscriptNov 30, 2023
- Roivant Sciences Ltd at Evercore ISI HealthCONx Conference TranscriptNov 29, 2023
- Roivant Sciences Ltd at Jefferies London Healthcare Conference TranscriptNov 15, 2023
- Q2 2024 Roivant Sciences Ltd Earnings Call TranscriptNov 13, 2023$9.05 (+2.72%)Earnings
- Roivant Sciences Ltd at Guggenheim Securities Inflammation & Immunology Conference TranscriptNov 07, 2023
- Roivant Sciences Ltd at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Roivant Sciences Ltd at Citi BioPharma Conference TranscriptSep 07, 2023
- Q1 2024 Roivant Sciences Ltd Earnings Call TranscriptAug 14, 2023$11.71 (+1.21%)Earnings
- Q4 2023 Roivant Sciences Ltd Earnings Call TranscriptJun 28, 2023$10.07 (+11.27%)Earnings
- Roivant Sciences Ltd to Review Results From the Chronic Period of TUSCANY-2 Investor Call TranscriptJun 22, 2023
- Roivant Sciences Ltd at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Roivant Sciences Ltd at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Roivant Sciences Ltd at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Roivant Sciences Ltd at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Roivant Sciences Ltd to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis Call TranscriptMar 15, 2023
- Q3 2023 Roivant Sciences Ltd Earnings Call TranscriptFeb 13, 2023$8.11 (+1.76%)Earnings
- Roivant Sciences Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Roivant Sciences Ltd at Goldman Sachs CEOs Unscripted Conference TranscriptJan 05, 2023
- Roivant Sciences Ltd to Announce Positive Results From the Induction Period of the TUSCANY-2 Call TranscriptJan 04, 2023
- Q2 2023 Roivant Sciences Ltd Earnings Call TranscriptNov 14, 2022$5.29 (+2.52%)Earnings
- Roivant Sciences Ltd at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Roivant Sciences Ltd Investor Day 2022 TranscriptSep 28, 2022
- Q1 2023 Roivant Sciences Ltd Earnings Call TranscriptAug 15, 2022$4.25 (-2.75%)Earnings
- Q4 2022 Roivant Sciences Ltd Earnings Call TranscriptJun 28, 2022$4.7 (+0.43%)Earnings
- Roivant Sciences Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Roivant Sciences Ltd Tapinarof FDA Approval Investor Call TranscriptMay 24, 2022
- Roivant Sciences Ltd at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Roivant Sciences Ltd to Provide Update Regarding Initiation of Patent Litigation Against Moderna - Conference Call TranscriptFeb 28, 2022
- Q3 2022 Roivant Sciences Ltd Earnings Call TranscriptFeb 14, 2022$7.2 (+5.11%)Earnings
- Roivant Sciences Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Q2 2021 Roivant Sciences Ltd Earnings Call TranscriptNov 15, 2021$8.08 (-3.81%)Earnings
- Q2 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences TranscriptNov 01, 2019
- Sumitomo Dainippon Pharma Co Ltd and Roivant Sciences Ltd Memorandum of Understanding for Strategic Alliance Call TranscriptSep 06, 2019
- 1